Long survival in childhood lymphoblastic leukaemia. by Chessells, J. M. et al.
Br. J. Cancer (1987), 55, 315-319
.9 The Macmillan
Long survival in childhood lymphoblastic leukaemia
J.M. Chessells', R.M. Hardistyl & S. Richards2
1Department ofHaematology and Oncology, Hospitalfor Sick Children, Great Ormond Street, London, WCIN 3JH and
2Clinical Trials Service Unit, Oxford, OX2, 6BR, UK.
Summary Long term follow-up of 378 children with acute lymphoblastic leukaemia (ALL) treated at a single
centre showed that at six years from diagnosis 202 (53%) were alive, of whom 140 (37%) remained in first
remission. Only three children had a first relapse after six years. Children who survived six years despite a
single extramedullary relapse in the testis or CNS were likely to remain in second remission but patients with
previous marrow or with multiple relapses continued at risk for up to ten years from diagnosis. Presenting
factors influencing event-free survival were: leucocyte count, age and sex. After allowing for these factors
morphological (FAB) subtype and liver enlargement retained their prognostic significance. Immunological
type of ALL was not of independent prognostic significance, except for the small number of patients with
B-ALL. Most factors lost their significance after 2-4 years.
It is concluded that patients alive 6 years from diagnosis without relapse or even with a single extra-
medullary relapse of ALL, have a high chance of prolonged survival and cure.
The definition of long survival in childhood lymphoblastic
leukaemia (ALL) is an arbitrary one. Earlier reports of long
survival have followed the fate of patients alive four years
from diagnosis (Till et al., 1973; Hardisty et al., 1981) with
emphasis on the importance of relapse-free survival and
many trials of treatment are reported after about this
duration of follow up. Since the introduction of 'modem'
therapy most children with ALL have been treated for two
or three years, and while most relapses occur either during
treatment or within a year of stopping it, later relapses may
occur (George et al., 1979). We have therefore examined the
outcome in all children referred to the Hospital for Sick
Children since the introduction of modern therapy, who
have been followed up for a minimum period of at least six
years, in order to ascertain the risk and pattern of later
relapses. We have also examined the outcome in children
who were alive six years from diagnosis after one or more
relapses, to determine which types of patient in this category
had a chance of long term survival.
Patients and methods
The patients comprise all children referred to the Hospital
for Sick Children for treatment of ALL between 1970 and
1979. All were treated on protocols devised or being piloted
for the Medical Research Council (MRC) Working Party on
Childhood Leukaemia which have been described in detail
elsewhere; (Chessells et al., 1981). All patients received
induction therapy with prednisolone, vincristine and at least
one other drug and continuing multiple agent chemotherapy.
Measures to prevent the development of overt leukaemic
inflitration of the central nervous system (CNS prophylaxis)
were used in all patients except those in UKALL I, (i.e.
those referred in 1970 and 1971) and comprised cranial
irradiation together with a course of intrathecal methotrexate
injections and/or spinal irradiation. Many patients were
involved in trials of optimal duration of chemotherapy,
reported elsewhere (MRC, 1982), the longest duration being
three years. Thus, at the time of analysis, all patients still in
their first remission had been off treatment for at least three
years.
Patients who had had a bone marrow relapse had received
a variety of treatments, many of which have been described
elsewhere (Chessells & Cornbleet, 1979; Chessells et al.,
1984). Management of extramedullary relapse evolved over
the period under review. Patients in the MRC UKALL I
(MRC 1973) trial did not receive CNS prophylaxis and a
large number developed CNS relapse, many of whom were
entered into the second MRC meningeal trial (Willoughby,
1976) which involved treatment of meningeal relapse with
intrathecal methotrexate and a subsequent randomised
comparison of cranial and craniospinal irradiation; patients
relapsing -later all received craniospinal irradiation as
previously described (Gribbin et al., 1977). The management
of children relapsing despite CNS prophylaxis evolved to a
standard policy of intrathecal chemotherapy, further
systemic intensification and further, craniospinal, irradiation
(Pinkerton & Chessells, 1984). Similarly the first few patients
with localized testicular relapses did not receive standard
chemotheraphy and radiotherapy, but subsequently all
patients were treated with bilateral testicular irradiation,
systemic reinduction and intensification, intrathecal
chemotherapy, and two years of further chemotherapy
(Tiedemann et al., 1982). All the patients have been followed
up for a minimum of 6 years from diagnosis and no patients
have been lost to follow-up.
Morphological and immunological analyses
Morphological (FAB) classification of the leukaemia as
originally described by Bennett et al. (1976), had been
carried out at diagnosis on the majority of patients. The
leukaemias had been classified immunologically by
techniques then available (Greaves et al., 1981) into c-ALL,
T-ALL, B-ALL and null-ALL
Statistical analyses
All statistical analyses were performed by the log-rank
method (Peto et al., 1977). After ascertainment of prognostic
variables by unstratified analysis, results were stratified by
the most important variables, leucocyte count and age, to
determine which were of independent prognostic significance.
In order to determine the duration of influence of prognostic
variables, analyses were done for each of the periods, up to
two years, two to four years and four to six years from
diagnosis.
Results
Long term disease-free survival afterfour and six years
Three hundred and seventy-eight children with ALL were
treated between 1970 and 1979 of whom 151 (40%) were
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alive in first remission at four years. Since previous analyses
had examined the outcome for patients from four years, we
looked first at follow up of all patients in remission at four
years and survival is shown for these 151 patients in Figure
1. It can be seen that the majority of relapses occurred in the
fifth and sixth year from diagnosis. Thus, at six years, our
time of minimum follow-up, 140 (37%) of all children and
93% of those in remission at four years, remained in
remission; two relapses occurred in the seventh year (fourth
year off treatment) and one in the eighth year. In all the
cases of late relapse the morphological and cytochemical
appearance of the leukaemic blast cells was consistent with
ALL and, where immunological characterization had been
performed, there was no evidence of alteration in phenotype;
there was thus no reason to suppose that these relapses
represented a new leukaemia.
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Figure 1 Disease-free survival for patients who were in first
complete remission at 4 years. The graph shows follow-up from
4 years. Figures indicate numbers at risk. The standard error at 5
years is + 1.9%, at 7.5 years +2.3% and at 10 and 12.5 years
+2.4%.
The 137 patients alive in first remission remain in general
well and a detailed analysis of their health is in preparation.
No second neoplasms have been observed among these six-
year disease-free survivors, although in the whole group of
378 children there have been three. One child developed
acute myeloid leukaemia two years from diagnosis and two
children developed second neoplasms after bone marrow
relapse, one Hodgkin's disease and one a cerebral
astrocytoma. All three patients died within 6 years from
diagnosis.
Survival after relapse
At six years from diagnosis there were 202 children alive of
whom 62 had survived after one or more relapses. Twenty-
one of these patients had relapsed on more than one
occasion before six years, and, as shown in Figure 2, they
continued thereafter at risk of further recurrence. Forty-one
children had survived to six years from diagnosis having had
a single relapse; Table I shows that these survivors comprise
a minority of all those relapsing. Only 22 of the 134 children
relapsing in the bone marrow, with or without concurrent
relapse in the CNS or testis were alive and in second
remission at six years and the risk of further relapse, as
Figure 2 Follow up of patients who were alive at 6 years after
one or more relapses. The curves indicate time to next relapse or
death. There are two patients with combined marrow and CNS
relapse included in the BM curve. The curve for multiple relapses
indicates patients who had survived for 6 years having had more
than one relapse.
Table I Six year survival after a single relapse
No. alive at
6 years in
Site ofrelapsea No. relapses second remission
Bone marrow+
other site 134 22
Central nervous system
Pre-prophylaxis
(standard therapy) 23 (9) 4 (4)
Post-prophylaxis
(standard therapy) 26 (13) 2 (2)
Testis (biopsy positive) 18 (6) 13 (6)
Total 201 41
aFifteen of 378 children did not achieve remission and 19 died in
first remission. One patient developed acute myelogenous leukaemia,
one relapsed in the eye and one in lymph nodes.
shown in Figure 2 continued after this time. Only 6 of the 49
patients experiencing CNS relapse as a first event survived in
next remission to six years. Table I shows both the
proportion of children relapsing in 1970 and 1971 before the
routine use of 'prophylaxis' and those relapsing later, and
also the proportion of children receiving what might in
retrospect be considered best standard therapy with re-
induction, intrathecal chemotherapy and craniospinal
irradiation. Although the proportion surviving to six years
was small thereafter none have subsequently relapsed.
Eighteen boys (Table I) had an isolated testicular relapse as
a first event and of these only one, a boy with B-ALL,
relapsed during treatment. The others, as shown in the table
all had a positive biopsy at two or three years of treatment
or developed a relapse after stopping treatment. One of these
17 children received no further treatment, two received local
irradiation alone and one received half the usual dose of
irradiation (12Gy instead of 24Gy) to his other clinically
uninvolved testis. Thus, 13 patients received standard
treatment of whom twelve remain in remission six years and
more from diagnosis. The failure on Figure 2 represents local
recurrence in the boy receiving the low irradiation dose.
Thus, it appears that if children with extramedullary disease
survive in second remission for six years they may achieve
long survival, that, as expected the outcome for the multiply
relapsed patient is uncertain, and that patients remain at
long term risk of recurrence for many years after bone
marrow relapse.
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Presentingfeatures in relation to long term survival
Table II shows the results of analysis of various clinical and
laboratory features at presentation in relation to survival to
six years with and without relapse. The factors have been
stratified to allow for the dominant effect of leucocyte count
on prognosis. Some factors related to the leukaemic cell
burden, such as enlargement of liver and spleen, retained
their prognostic significance after stratification whereas the
effect of enlargment of lymph nodes and presence of a
mediastinal mass was no longer significant. As expected age
was a significant prognostic factor for both survival and
event-free survival. Whereas in this series fewer males
survived relapse-free to six years their overall survival was
equivalent to that of the females. The difference in event-free
survival was largely due to testicular relapse since there was
no significant difference in marrow relapse rate between boys
and girls at two, four or six years from diagnosis.
Morphological and immunological classification had not
been performed on all cases but the morphological (FAB)
subtype retained prognostic significance when allowance was
made for leucocyte count. The immunological subtype of
ALL was significant because of the poor prognosis of the
small number of patients with B-ALL. Comparison of c-
ALL vs. T-ALL shows that after stratification for leucocyte
count the significant difference between the groups is lost.
In Table III results are progressively stratified by the most
important variables. After allowing for leucocyte count, age
and sex, both liver enlargement and FAB type retain their
significance.
Duration ofinfluence ofprognosticfactors
Table IV shows the results of analysis of the duration of
influence of the factors influencing prognosis. It can be seen
Table II Factors influencing survival
6 year survival
Infirst remission
Total Alive
no. no. no. Stratified
Presentingfeature 378 202 P 140 P P
NS 69
71
9
0.0006a
118
13
131
NS
0
7
2
82
21
<0.00005
18
12
7
58
<0.00005
82
62
0.0001
78
41
0.008
0.005
NS
99
130
9
89
50
0.03 66
34
39
0.0001 84
40
65
<0.00005' 8
0
4
0.01 0.02
0.002a 0.02a
NSa NSa
<0.00005
<0.00005 0.002
0.0001 0.009
0.02
0.02
NS
NS
NS NS
0.004 NS
0.0005 0.0008
<0.00005a <0.00005a
Male
Female
<2
2-10
10+
Caucasian
Negro
Indian
Other
<10
10-
20-
50-
100-
No
Yes
No
218
160
41
294
43
349
8
17
4
192
52
56
35
43
114
264
126
116
86
13
167
22
190
2
8
2
119
31
27
15
10
78
124
84
Sex
Age
Race
WBC
x 1091-1
Liver
Enlarged
Spleen
Enlarged
Nodes
Enlarged
Med.
mass
(367)
HBgdl -'
(377)
Platelets
(377)
x1091-1
FAB
(296)
Cell
type
(201)
Yes
No
Yes
No
Yes
<8
252 118
90 58
288 144
334 185
33 12
250 136
8+
<40
40-
100+
LI
L2
C
T
B
Null
127
204
97
76
172
124
151
30
3
17
65
104
47
50
111
53
88
10
0
5
C vs. 151 88 65
T 30 10 0.0006 8 0.0025 0.1
ap value for heterogeneity, not trend.318 J.M. CHESSELLS et al.
Table III Event free survival at 6 years Factors of independent
prognostic significance
Factor Initial WBC +Age +Sex +FAB type
Age 0.02
Sex 0.02 0.02
Liver size 0.002 0.004 0.005 0.04
Spleen size 0.009 0.03 0.04 NS
FAB type 0.0008 0.0001 0.0004
Cell type <0.00005 <0.00005 <0.00005 NS
Common vs. T 0.1 0.1 0.1 NS
Table IV Duration of influence of prognostic factors for
event-free survival
Factor At 2 yrs 2-4 yrs 4-6 yrs
Sex 0.1 0.02 0.2
Agea 0.0009 0.5 0.5
WBC 0.0005 0.1 0.05
Liver size 0.0006 0.02 0.2
Spleen size 0.002 0.006 0.5
FAB subclass 0.0001 0.2 0.3
Phenotypea
C vs T 0.00005 0.8 0.7
ap =value for heterogeneity.
that the majority of those associated with leukaemic cell
mass, e.g. leucocyte count, and enlargement of liver and
spleen, exert their influence maximally in the first two years
and have no influence after 2-4 years, although leucocyte
count appears of marginal significance at 4-6 years.
Similarly, age, cell phenotype and FAB subclass are not
significant after 2 years. By contrast the effect of sex is only
apparent at 2-4 years from diagnosis. Thus, with the
exception of sex, most recognized adverse prognostic factors
in this series had lost their significance by two, or at most
four, years from diagnosis and did not influence the chance
of long-term survival beyond that time.
Discussion
At a minimum of six years from diagnosis 53% of the
children were alive, one third of survivors having experienced
at least one relapse. The importance of maintenance of initial
remission is emphasized by the facts that 90% of the
children who were alive in remission at four years have
continued to survive relapse-free. Only three relapses have
occurred so far beyond six years, two of these in the seventh
year. It is perhaps significant that two of these three very
late relapses occurred in a group of children receiving
intermittent maintenance chemotherapy in a pilot protocol
for the national MRC UKALL V trial (Rapson et al., 1980)
and that a number of late relapses have subsequently been
observed in this trial (MRC 1986). While our study has the
advantage of complete follow-up and the inclusion of all
patients seen at a single centre, it does suffer from the
disadvantage that the patients received a variety of treat-
ments and that the likelihood of late relapse may vary
according to therapeutic schedule. Nevertheless these results
are remarkably similar to those originally reported from St
Jude Children's Research Hospital (George et al., 1979)
when with a minimum follow-up of three years, and all
patients treated for two and a half years, the authors
observed few relapses in patients more than four years off
therapy; a recent follow-up from the same centre estimates
that the relapse rate is less than 2% in patients off therapy
for more than three years (Rivera & Simone, 1985). In a
multi-institutional study of duration of therapy, the
American Children's Cancer Study Group (CCSG) found
that no patient surviving more than three years off therapy
had subsequently relapsed (Nesbit et al., 1983). It seems
therefore that the child who survives relapse-free for six
years has a high chance of cure.
By contrast, the prognosis for patients surviving despite
relapse was variable. Previous reports of long survival have
emphasized the poor prognosis of relapsed patients but not
always looked at outcome by site of relapse. Our proportion
of long survivors with relapse is similar to that reported
from St. Jude's (Rivera & Simone, 1985), but no mention is
made of long term outcome in their group. Our results
suggest that, as we have previously reported, boys with
isolated testicular relapse may achieve long term remissions
and even cure (Tiedemann et al., 1982). We have previously
shown that patients who develop overt CNS relapse, with or
without previous prophylaxis, are at high risk of subsequent
marrow relapse, (Pinkerton & Chessells, 1984) but the
present results suggest that if marrow remission is
maintained for six years from diagnosis without further
recurrence of CNS disease, long term remission and perhaps
cure, is possible for some patients.
The results in patients surviving after bone marrow relapse
or multiple relapses are in contrast to these findings and
confirm our previous reports (Chessells & Cornbleet, 1979;
Chessells et al., 1984). Whether this picture will be improved
by the use of more intensive rescue therapy such as chemo-
radiotherapy and bone marrow transplantation remains to
be seen, but seems unlikely from our recent experience
(Chessells et al., 1986).
The dominant prognostic factors influencing the chance of
long term remission are, as in most studies, the extent of the
disease at presentation as reflected in the height of the
leucocyte count and the enlargement of organs, and the age
of the patient. The FAB (morphological) subclass of ALL
was assigned to the patients without the use of the more
recent scoring system (Bennett et al., 1981) but even so it
retained, as in other reported series (Hann et al., 1979;
Miller et al., 1981), a strong prognostic significance. The
prognostic significance of the immunological subclass of
ALL had previously been unclear: we originally reported
that immunological subclass was of prognostic significance
(Chessells et al., 1977) but in an analysis of MRC data
(Greaves et al., 1981) it appeared that the adverse effect of
T-ALL was due solely to its association with a high
leucocyte count. Follow-up at the time of the latter report
was short, and in the present study with long-term follow-up
it seems confirmed that apart from the well known poor
prognosis of B-ALL, once allowance is made for leucocyte
count, the outcome for patients with T-ALL is no worse
than that of those with c- or nul-ALL. At the time of our
study patients with c-ALL were not further classified by pre-
B subtype, so we are unable to confirm or disprove recent
reports that patients with pre-B-ALL have a relatively poor
prognosis (Crist et al., 1984). These presenting features are
of prognostic significance for the first two, or at the most,
four years, but lose their significance thereafter. This dis-
appearance of predictive value was noted by the CCSG
(Sather et al., 1981) in a study with maximum follow-up to
five years. The influence of sex on prognosis however is
maximal at two to four years, a period approximating to the
first year off therapy, but no longer significant at six years.
This report indicates that thirty to forty percent of an
unselected group of all children with ALL presenting to a
single centre during this ten-year period have been cured. It
is difficult to compare these cure rates in all patients treated
at a single centre with results reported from multicentre
trials, both because of unknown selection in entry of patients
to trials and the regrettable tendency for early publication of
results. These results seem similar to those reported on long
term follow up of patients treated during this period at St
Jude Children's Hospital (Rivera & Simone, 1985) but
inferior to multi-institutional studies such as those of theCHILDHOOD LYMPHOBLASTIC LEUKAEMIA SURVIVAL 319
CCSG (Miller et al., 1980) and the West German BFM
group (Riehm et al., 1983). Our results confirm that the
factors determining prognosis were the long recognized ones
of leukaemic mass and age, and also the immunological and
morphological subtype of ALL. The child who survives the
first two years despite adverse prognostic factors, has
however as good a chance of cure. It is to be hoped that the
more intensive therapy now given, by preventing relapse in
the first two years, will increase the chance of long term
remission for the child with ALL.
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